Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neural Transmission
Published in: Journal of Neural Transmission 2/2012

01-02-2012 | Basic Neurosciences, Genetics and Immunology - Review article

Kynurenines in Parkinson’s disease: therapeutic perspectives

Authors: Dénes Zádori, Péter Klivényi, József Toldi, Ferenc Fülöp, László Vécsei

Published in: Journal of Neural Transmission | Issue 2/2012

Login to get access

Abstract

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder the pathomechanism of which is not yet fully known. With regard to the molecular mechanism of development of the disease, oxidative stress/mitochondrial impairment, glutamate excitotoxicity and neuroinflammation are certainly involved. Alterations in the kynurenine pathway, the main pathway of the tryptophan metabolism, can contribute to the complex pathomechanism. There are several possibilities for therapeutic intervention involving targeting of this altered metabolic route. The development of synthetic molecules that would shift the altered balance towards the achievement of neuroprotective effects would be of great promise for future clinical studies on PD.
Literature
Acuna-Castroviejo D, Tapias V, Lopez LC, Doerrier C, Camacho E, Carrion MD, Mora F, Espinosa A, Escames G (2011) Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in mice. Brain Res Bull 85:133–140PubMedCrossRef
Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 104:14807–14812PubMedCrossRef
Bahn A, Ljubojevic M, Lorenz H, Schultz C, Ghebremedhin E, Ugele B, Sabolic I, Burckhardt G, Hagos Y (2005) Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol 289:C1075–C1084PubMedCrossRef
Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta 1792:651–663PubMed
Battie C, Verity MA (1981) Presence of kynurenine hydroxylase in developing rat brain. J Neurochem 36:1308–1310PubMedCrossRef
Behan WM, McDonald M, Darlington LG, Stone TW (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 128:1754–1760PubMedCrossRef
Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23:228–242PubMedCrossRef
Bereczki D (2010) The description of all four cardinal signs of Parkinson’s disease in a Hungarian medical text published in 1690. Parkinsonism Relat Disord 16:290–293PubMedCrossRef
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306PubMedCrossRef
Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 151:313–315PubMedCrossRef
Blandini F (2010) An update on the potential role of excitotoxicity in the pathogenesis of Parkinson’s disease. Funct Neurol 25:65–71PubMed
Borza I, Kolok S, Galgoczy K, Gere A, Horvath C, Farkas S, Greiner I, Domany G (2007) Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 17:406–409PubMedCrossRef
Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson’s disease. NeuroRx 2:484–494PubMedCrossRef
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
Bredt DS (1999) Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 31:577–596PubMedCrossRef
Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192PubMed
Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823:1–10PubMedCrossRef
Butler EG, Bourke DW, Finkelstein DI, Horne MK (1997) The effects of reversible inactivation of the subthalamo-pallidal pathway on the behaviour of naive and hemiparkinsonian monkeys. J Clin Neurosci 4:218–227PubMedCrossRef
Camacho E, Leon J, Carrion A, Entrena A, Escames G, Khaldy H, Acuna-Castroviejo D, Gallo MA, Espinosa A (2002) Inhibition of nNOS activity in rat brain by synthetic kynurenines: structure-activity dependence. J Med Chem 45:263–274PubMedCrossRef
Caudle WM, Zhang J (2009) Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 220:230–233PubMedCrossRef
Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574–578PubMedCrossRef
Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK (2010) The role of neuroinflammation on the pathogenesis of Parkinson’s disease. BMB Rep 43:225–232PubMedCrossRef
Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5:77–82PubMed
Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93:868–876PubMed
Csillik AE, Okuno E, Csillik B, Knyihar E, Vecsei L (2002) Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex 12:1193–1201PubMedCrossRef
de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21–S23PubMed
Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283:9089–9100PubMedCrossRef
Eastman CL, Guilarte TR (1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15:1101–1107PubMedCrossRef
Escames G, Leon J, Macias M, Khaldy H, Acuna-Castroviejo D (2003) Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 17:932–934PubMed
Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MA, Colton CA (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8:431–434PubMedCrossRef
Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J (1999) A chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor. Hum Mol Genet 8:81–85PubMedCrossRef
Fornstedt-Wallin B, Lundstrom J, Fredriksson G, Schwarcz R, Luthman J (1999) 3-Hydroxyanthranilic acid accumulation following administration of the 3-hydroxyanthranilic acid 3, 4-dioxygenase inhibitor NCR-631. Eur J Pharmacol 386:15–24PubMedCrossRef
Foster AC, White RJ, Schwarcz R (1986) Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem 47:23–30PubMedCrossRef
Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017PubMedCrossRef
Fulop F, Szatmari I, Vamos E, Zadori D, Toldi J, Vecsei L (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16:4828–4842PubMedCrossRef
Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol 51:296–301PubMedCrossRef
Gal EM, Sherman AD (1978) Synthesis and metabolism of l-kynurenine in rat brain. J Neurochem 30:607–613PubMedCrossRef
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918–934PubMedCrossRef
Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 47:PL91–PL97PubMedCrossRef
Gregoire L, Rassoulpour A, Guidetti P, Samadi P, Bedard PJ, Izzo E, Schwarcz R, Di Paolo T (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 186:161–167PubMedCrossRef
Guidetti P, Wu HQ, Schwarcz R (2000) In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum. Exp Neurol 163:123–130PubMedCrossRef
Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R (2007) Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 102:103–111PubMedCrossRef
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842–853PubMedCrossRef
Hallman H, Olson L, Jonsson G (1984) Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur J Pharmacol 97:133–136PubMedCrossRef
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781–785PubMedCrossRef
Han Q, Cai T, Tagle DA, Li J (2010) Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 67:353–368PubMedCrossRef
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci 239:31–35PubMedCrossRef
Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473PubMed
Javoy F, Sotelo C, Herbet A, Agid Y (1976) Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res 102:201–215PubMedCrossRef
Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319–1328PubMedCrossRef
Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, Chung J (2008) PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 377:975–980PubMedCrossRef
Kiss C, Vecsei L (2009) Kynurenines in the brain: preclinical and clinical studies, therapeutic considerations. In: Lajtha A (ed) Handbook of neurochemistry and molecular neurobiology, 3rd edn., Brain and Spinal Cord Trauma. Springer-Verlag, Berlin, Heidelberg, pp. 91–105
Knyihar-Csillik E, Csillik B, Pakaski M, Krisztin-Peva B, Dobo E, Okuno E, Vecsei L (2004) Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment. Neuroscience 126:899–914PubMedCrossRef
Knyihar-Csillik E, Chadaide Z, Mihaly A, Krisztin-Peva B, Fenyo R, Vecsei L (2006) Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol 112:127–137PubMedCrossRef
Langston JW, Ballard PA Jr (1983) Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med 309:310PubMed
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980PubMedCrossRef
Langston JW, Irwin I, Langston EB, Forno LS (1984) 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48:87–92PubMedCrossRef
Lee do Y, Lee KS, Lee HJ, Noh YH, Kim do H, Lee JY, Cho SH, Yoon OJ, Lee WB, Kim KY, Chung YH, Kim SS (2008) Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol 87:389–397PubMedCrossRef
Leon J, Vives F, Crespo E, Camacho E, Espinosa A, Gallo MA, Escames G, Acuna-Castroviejo D (1998a) Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J Neuroendocrinol 10:297–302PubMedCrossRef
Leon J, Vives F, Gomez I, Camacho E, Gallo MA, Espinosa A, Escames G, Acuna-Castroviejo D (1998b) Modulation of rat striatal glutamatergic response in search for new neuroprotective agents: evaluation of melatonin and some kynurenine derivatives. Brain Res Bull 45:525–530PubMedCrossRef
Leon J, Macias M, Escames G, Camacho E, Khaldy H, Martin M, Espinosa A, Gallo MA, Acuna-Castroviejo D (2000) Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol Pharmacol 58:967–975PubMed
Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27:2846–2857PubMedCrossRef
Luchowski P, Luchowska E, Turski WA, Urbanska EM (2002) 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett 330:49–52PubMedCrossRef
Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M (2002) Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80:1071–1078PubMedCrossRef
Marosi M, Nagy D, Farkas T, Kis Z, Rozsa E, Robotka H, Fulop F, Vecsei L, Toldi J (2010) A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm 117:183–188PubMedCrossRef
Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y (1997) Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2–27. Am J Hum Genet 60:588–596PubMed
McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119–127PubMedCrossRef
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291PubMed
Meredith GE, Totterdell S, Beales M, Meshul CK (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol 219:334–340PubMedCrossRef
Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2, 3-dione and 2, 3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem 73:750–757PubMedCrossRef
Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K (1997) Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78:967–975PubMedCrossRef
Mizuno Y, Sone N, Saitoh T (1987) Effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 48:1787–1793PubMedCrossRef
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210PubMedCrossRef
Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16PubMedCrossRef
Mortiboys H, Johansen KK, Aasly JO, Bandmann O (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017–2020PubMedCrossRef
Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11:999–1016PubMedCrossRef
Nemeth H, Toldi J, Vecsei L (2006) Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl 70:285–304
Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci 36:2503–2508PubMedCrossRef
Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S (1992) Kynurenine pathway abnormalities in Parkinson’s disease. Neurology 42:1702–1706PubMed
Okuda S, Nishiyama N, Saito H, Katsuki H (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70:299–307PubMedCrossRef
Okuno E, Nakamura M, Schwarcz R (1991) Two kynurenine aminotransferases in human brain. Brain Res 542:307–312PubMedCrossRef
Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Gregoire L, Meltzer LT, Di Paolo T (2009) Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61–8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 38:128–142PubMedCrossRef
Papai Pariz F (1690) Pax corporis, az az az emberi testnek belső nyavalyáinak okairól, fészkeiről ‘s azoknak orvoslásának módgyáról való tracta…, (“Pax corporis, i.e. a teaching of the causes, sources and the methods of treatment of the internal diseases of the human body”). Nemethi Mihaly, Kolozsvár
Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely and Jones, London
Parli CJ, Krieter P, Schmidt B (1980) Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch Biochem Biophys 203:161–166PubMedCrossRef
Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184–187PubMedCrossRef
Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J (2007) The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat Cell Biol 9:1243–1252PubMedCrossRef
Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21–q23. Science 274:1197–1199PubMedCrossRef
Prescott C, Weeks AM, Staley KJ, Partin KM (2006) Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402:108–112PubMedCrossRef
Reggiani A, Maraia G, Ceserani R, Gaviraghi G (1989) Effect of 7-chloro kynurenic acid on glycine modulation of the N-methyl-D-aspartate response in guinea-pig myenteric plexus. Eur J Pharmacol 168:123–127PubMedCrossRef
Reichmann H, Riederer P (1989) Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson’s disease, BMFT Symposium “Morbus Parkinson und andere Basalganglienerkrankungen”, Bad Kissingen, p 44 (abstract)
Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski P, Banerjee R, Gendelman HE (2008) Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3:59–74PubMedCrossRef
Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16:1139–1143PubMedCrossRef
Roberts RC, Du F, McCarthy KE, Okuno E, Schwarcz R (1992) Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol 326:82–90PubMedCrossRef
Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann Neurol 44:S175–S188PubMed
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139PubMedCrossRef
Rozsa E, Robotka H, Vecsei L, Toldi J (2008) The Janus-face kynurenic acid. J Neural Transm 115:1087–1091PubMedCrossRef
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269PubMedCrossRef
Schuler F, Casida JE (2001) Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling. Biochim Biophys Acta 1506:79–87PubMedCrossRef
Schwarcz R (1993) Metabolism and function of brain kynurenines. Biochem Soc Trans 21:77–82PubMed
Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4:12–17PubMedCrossRef
Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1–10PubMedCrossRef
Silva-Adaya D, Perez-De La Cruz V, Villeda-Hernandez J, Carrillo-Mora P, Gonzalez-Herrera IG, Garcia E, Colin-Barenque L, Pedraza-Chaverri J, Santamaria A (2011) Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303–312PubMedCrossRef
Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379PubMed
Stone TW (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21:149–154PubMedCrossRef
Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609–620PubMedCrossRef
Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411–412PubMedCrossRef
Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Kruger R (2005) Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet 14:2099–2111PubMedCrossRef
Tavares RG, Tasca CI, Santos CE, Alves LB, Porciuncula LO, Emanuelli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621–627PubMedCrossRef
Tiszlavicz Z, Nemeth B, Fulop F, Vecsei L, Tapai K, Ocsovszky I, Mandi Y (2011) Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-alpha (TNF-alpha) production by mononuclear cells, HMGB1 production by monocytes and HNP1–3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol 383:447–455PubMedCrossRef
Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110PubMedCrossRef
Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet 68:895–900PubMedCrossRef
van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69:629–634PubMedCrossRef
Varga G, Erces D, Fazekas B, Fulop M, Kovacs T, Kaszaki J, Fulop F, Vecsei L, Boros M (2010) N-Methyl-d-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol Motil 22:217–225 (e68)PubMedCrossRef
Vecsei L (2005) Kynurenines in the brain. From experiments to clinics. Nova, New York
Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021–22028PubMedCrossRef
Wolf H (1974) The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 136:1–186PubMed
Wu HQ, Lee SC, Schwarcz R (2000) Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J Pharmacol 390:267–274PubMedCrossRef
Yang H, Zhou HY, Li B, Niu GZ, Chen SD (2007) Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells. J Neuroimmune Pharmacol 2:276–283PubMedCrossRef
Yu P, Li Z, Zhang L, Tagle DA, Cai T (2006) Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365:111–118PubMedCrossRef
Zadori D, Klivenyi P, Vamos E, Fulop F, Toldi J, Vecsei L (2009) Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116:1403–1409PubMedCrossRef
Zadori D, Ilisz I, Klivenyi P, Szatmari I, Fulop F, Toldi J, Vecsei L, Peter A (2011a) Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J Pharm Biomed Anal 55:540–543PubMedCrossRef
Zadori D, Klivenyi P, Plangar I, Toldi J, Vecsei L (2011b) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701–717PubMedCrossRef
Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, Freund TF, Vecsei L, Klivenyi P (2011c) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J Neural Transm 118:865–875PubMedCrossRef
Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19:533–542PubMedCrossRef
Metadata
Title
Kynurenines in Parkinson’s disease: therapeutic perspectives
Authors
Dénes Zádori
Péter Klivényi
József Toldi
Ferenc Fülöp
László Vécsei
Publication date
01-02-2012
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 2/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0697-3

Other articles of this Issue 2/2012

Journal of Neural Transmission 2/2012 Go to the issue

Basic Neurosciences, Genetics and Immunology - Review article

Involvement of kynurenines in Huntington’s disease and stroke-induced brain damage

Basic Neurosciences, Genetics and Immunology - Original Article

Behavioural studies with a newly developed neuroprotective KYNA-amide

Editorial

Kynurenines and the nervous system: therapeutic perspectives

Basic Neurosciences, Genetics and Immunology - Original Article

Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice

Basic Neurosciences, Genetics and Immunology - Original Article

Preparation and properties of nanoscale containers for biomedical application in drug delivery: preliminary studies with kynurenic acid

Basic Neurosciences, Genetics and Immunology - Original Article

New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio